Monthly Archives: February 2019

Expedia Group is the largest travel intermediary with gross bookings of over USD100 billion.

Expedia Group is the largest travel intermediary with gross bookings of over USD100 billion. In 2017 company sales slowed down and 2018 saw further stagnation, although at 13% growth remains healthy. The battle for supremacy with Booking Holdings continues, with meta-search a key battleground. Using the latest technological innovations such as VR and voice, and a strong focus on mobile, Expedia hopes to stay ahead of the competition.

Expedia Group Inc in travel Market Research Reports.jpg

Expedia Group Inc in Travel (World) Company Profile offers detailed strategic analysis of the company’s business, examining its performance in the Travel market. The report examines company shares by region, financial performance, its marketing strategies, challenges from the competition and future prospects. Use it to understand opportunities and threats facing the business and the factors driving success.

Product coverage:

Activities (Destination)

Lodging

Online Travel Sales and Intermediaries

Tourism Flows

Travel Modes

Traveler Profiles.


Data coverage:

Market sizes (historic and forecasts)

Company shares

Brand shares

Distribution data


Why buy this report?

Get a detailed picture of the Travel market;

Pinpoint growth sectors and identify factors driving change;

Understand the competitive environment, the market’s major players and leading brands;

Use five-year forecasts to assess how the market is predicted to develop.

CategoryTravel and Tourism Market

Contact Details:

Aarkstore Enterprise
24/7 Online Support: +91 9987295242 | contact@aarkstore.com

Advertisements

Around 70% of respondents have opted for UK Private Motor Insurances

UK Private Motor Insurance Market report explores consumer purchasing behavior, and how preferences are changing over time. It discovers what is most influential to customers when purchasing a policy, and also reveals the most popular providers in the market. New trends and innovations are highlighted, as well as the key factors that will influence the private motor insurance market over the next few years.

UK Private Motor Insurance Market

The purchasing preferences of private motor insurance customers changed in 2018. Price comparison websites (PCWs) are now the most popular channel, used by 37.4% of respondents. In a period of record high premiums, customer loyalty has waned: 63.4% of respondents used a PCW to conduct research before buying their latest policy. With the rising prominence of PCWs, more customers are also shifting their purchasing methods online, with approximately 70% of respondents purchasing their motor insurance policy either on a PC or handheld device.

Scope

– 37.4% of private motor insurance customers purchased via a price comparison website in 2018.

– 69.8% of customers purchased online.

– 13.2% of customers held a policy with Admiral.

– 72.5% of customers shopped around at last renewal.

Reasons to buy

– Understand consumer purchasing decisions and how these will influence the market over the next few years.

– Improve customer engagement by recognizing what is most important to them and how to adapt products and services to meet their needs.

– Learn which providers lead the way in the private motor insurance space.

– Discover which insurers spend the most on advertising and which channels they are using.

Category: Finance and Banking Market

Contact Details:

Aarkstore Enterprise

Phone: 91 – 998 729 5242 | contact@aarkstore.com

A distinct SWOT portrait of Deleum Berhad.

Summary

Deleum Berhad (Deleum), formerly Deleum Sdn Bhd, is an oil and gas company that offers oilfield consulting services. The company operates through its business divisions such as power and machinery, oilfield services and maintenance, and integrated corrosion solutions. Its oilfield services and maintenance business includes a provision of wire-line equipment and services, integrated wellhead maintenance, provision of oilfield chemicals and technical services. Deleums power and machinery business comprise the provision of gas turbine packages, a supply of gas turbine parts, maintenance and installation of valves and flow regulators, and others. The company also provides repair and overhaul of motors generators, transformers, and pumps. It has operations throughout Malaysia. Deleum is headquartered in Kuala Lumpur, Malaysia.

DELEUM BERHAD (DELEUM)

Deleum Berhad Key Recent Developments

Feb 26,2018: Deleum Announces Quarterly Report On Consolidated Results For Financial Period Ended 31 Dec 2017

This comprehensive SWOT profile of Deleum Berhad provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers, and competitors better.

This company report forms part of GlobalDatas Profile on Demand service, covering over 50,000 of the worlds leading companies. Once purchased, GlobalDatas highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Deleum Berhad including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including

– Business description A detailed description of the company’s operations and business divisions.
– Corporate strategy Analysts summarization of the company’s business strategy.
– SWOT Analysis A detailed analysis of the company’s strengths, weakness, opportunities, and threats.
– Company history Progression of key events associated with the company.
– Major products and services A list of major products, services, and brands of the company.
– Key competitors A list of key competitors to the company.
– Key employees A list of the key executives of the company.
– Executive biographies A brief summary of the executive’s employment history.
– Key operational heads A list of personnel heading key departments/functions.
– Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
– Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

See full link:  https://www.aarkstore.com/oil-gas/69945/deleum-berhad-deleum-financial-and-strategic-swot-analysis-review 

Free Sample Request:  https://www.aarkstore.com/sample/69945

Category: Oil and Gas Market 

Contact Us: +91 9987295242   |   contact@aarkstore.com

 

 

Market for CAR-T Cell Therapy

Cell Therapy

Aarkstore Enterprise culminates the newest Market Research Report “Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends

EXECUTIVE SUMMARY

CAR-T cell therapy is a remarkably promising treatment for cancer patients. This emerging treatment represents one of the biggest breakthroughs since the introduction of chemotherapy.

In 2017, the world witnessed a historic CAR-T cell therapy approval when on August 30, 2017, Tisagenlecleucel (Kymriah) was approved by U.S. FDA for the treatment of children and young adults with acute lymphoblastic leukemia (ALL). On May 1, 2018, FDA approved Kymriah for a second indication (diffuse large B-cell lymphoma). By October 18, 2017, the FDA granted approval for Yescarta for treating patients with relapsed/refractory diffuse large B-cell lymphoma (r/rDLBCL) and other rare large B-cell lymphomas. Other notable approvals for CAR-T cell therapy products have also been achieved.

In August 2018, Kymriah and Yescarta secured approval in Europe, indicating the willingness of European regulators to usher in a new age of regenerative medicine. Novartis’ Kymriah was given marketing authorization in the EU for the treatment of blood cancers, including B-cell acute lymphoblastic leukaemia (ALL) and relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Gilead/Kite Pharma’s Yescarta was authorized as a treatment for adult patients with relapsed or refractory DLBCL and primary mediastinal large B-cell lymphoma (PMBCL). Health Canada approved Kymriah as the first CAR-T therapy in Canada and the Therapeutic Goods Administration (TGA) approved it as the first CAR-T therapy in Australia.

What is CAR-T Cell Therapy?

Chimeric antigen receptors (CARs) are genetically engineered cells that are developed in the laboratory and infused into a patient to help in detecting and fighting cancer. The protein constructs stimulate anti-cancer T-cells, which in turn boost a patient’s immune system. CAR-T cell therapy is defined as a type of immunotherapy that teaches T cells to recognize and destroy cancer.
CAR-T is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”

How Does CAR-T Cell Therapy Work?

T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and they play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally. Once infused into the patient, these CARs enable the T-cells recognize and get attached to an antigen (specific protein) on the tumor cell leading to the destruction of the tumor.

Like all cancer therapies, CAR-T cell therapy can also cause a number of side effects. However, all these side effects can be managed with standard supportive therapies including steroids. The widespread research activities, worldwide clinical trials and treatments in a limited number of U.S. hospitals have created a robust CAR T-cell market. This billion dollar market and projected growth would have been not possible without the remarkable efficacy of Kymriah and Yescarta in treating several types of blood cancers.

Market for CAR-T Cell Therapy

CAR-T cell therapy has swept the biotech industry by storm in recent years, creating hope that it could welcome in a new age of cancer treatment. However, the remarkable success stories have come from targeting CD19, which is now considered an antigen that holds the key to a limited range of blood cancers. Presently, this hematological arena is a highly competitive therapy space that is being shared between among leading CAR-T companies.

Scientists, investors and developers invariably agree that the key to longer-term success in this space depends on solving two major problems: identifying antigens other than CD19 that can be targeted with CAR-T therapy with strong efficacy and going beyond liquid cancers into solid tumor indications. CAR-T cell products to deal with solid tumors will undoubtedly offer a larger market potential.

However, it is not an easy task to identify the antigens found on the cells of solid tumors. There are reasons why CD19 is the most common target. It is seen solely on B cells, whose destruction via CAR-T therapy offers a straightforward route for treating B-cell leukemias and lymphomas. At the same time, loss of the body’s B cells is not particularly problematical, because their antibody-producing function can be reinstated by injecting intravenous immunoglobulin (IVIG) to patients.

Currently, the only two non-CD19-directed CAR-T therapies are those that target CD22 in B-cell malignancies and B-cell maturation antigen (BCMA) in multiple myeloma. CD22 is structurally analogous to CD19, while BCMA is an antigen expressed on plasma cells, whose functional loss can also be replaced with IVIG.

The problem with solid tumors is that there is little evidence of CAR-T being able to overcome the numerous difficulties that exist for these to be targeted efficiently. However, both academic and commercial groups are racing against time to identify the antigens on solid tumor cells and develop suitable CAR-T cells, because it represents large market potential.
There are several reasons which make solid tumors difficult to treat using CAR-T cell therapies. Globally, solid tumors outnumber the hematological tumors by 10 to one. In 2015, Novartis and PENN reported that their CART-meso failed to show any effect in patients with mesothelioma, ovarian cancer and pancreatic cancer. Moreover, there was very poor persistence of CAR-T cells in the patients.

The difficulty with solid tumors is that they are usually surrounded by a hostile, immuno-suppressive microenvironment. This environment presents many inhibitory factors that prevent CAR-T cells from reaching them. A typical CAR-T approach will not have success under these conditions. For this reason, Juno and Novartis are engaging in constructing CAR-T cells with novel designs that incorporate additional elements to boost activity within this setting. Currently, these products are in preclinical development.

Driving Forces for the CAR-T Therapy Market

With growing demand for CAR-T therapies, CAR-T companies are proliferating. Growing numbers of these companies are supported by:
• Increasing investment flowing into CAR-T cell research
• Landmark approvals of CAR-T cell therapies by the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA)
• Major acquisitions within the CAR-T industry
• Large IPOs within the CAR-T industry

As mentioned, 2017 was the first year that the U.S. FDA approved a CAR-T cell therapy, approving Kymriah in August 2017 and Yescarta in October 2017. Novartis produced Kymriah, a CAR-T therapy used to treat leukemia, while Gilead/Kite Pharma developed Yescarta, a CAR-T therapy for patients with lymphomas. Approvals for these products are now spreading globally, with authorizations permitted by the EU, Canada, and Australia, among others. The approval of these early CAR-T cell therapies has opened the gates for many other types of cell and gene therapies to claim respect, both from regulators, as well as from the broader scientific and medical communities.
CAR-T funding is also on the rise. At first the trend was subtle, but the tide swelled as CAR-T therapies like Kymriah and Yescarta reached the marketplace and created a CAR-T funding craze. CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine. Following IPOs by CAR-T players Kite Pharma, Bellicum, Juno Therapeutis and Cellectis totaling over $750 million, CAR-T developer Autolus announced a $150 million IPO.
This has bought the total value of recent CAR-T initial public offerings (IPO’s) to nearly $1 billion.

CAR-T Industry Deal-Making

The CAR-T industry has also witnessed aggressive deal-making in recent years. Celgene snagged Juno Therapeutics for a shocking $9 billion in January 2018 and Gilead acquired Kite Pharma for an astounding $11.9 billion in August 2017. After $20 billion of market capitalization from the CAR-T companies in 2018, the CAR-T market has continued to gain momentum.
There have also been more than a dozen CAR-T deals between pharmaceutical companies and academic institutions, with the best known being the partnership between Novartis and the University of Pennsylvania (UPenn). When Kymriah™ because the first CAR-T cell therapy to be approved in the U.S. in August 2017, it resulted from a 5-year collaboration between UPenn and Novartis.

CAR-T financing rounds have also proliferated. In one major example, Celularity raised $250 million in February 2018 to support development of placental-derived products, including T-cells that will be immune advantaged because of their derivation from the placenta. Celularity is looking to burst a major bottleneck in the industry by deriving T-cells from a single (allogeneic) cell line, potentially positioning itself to slash the price point for CAR-T treatments. In other significant example, London-based CAR-T start-up Allogene Therapeutics entered into an asset contribution deal with Pfizer in April 2018, as well as announced a $300 million Series A round.

To better understand and compete within the rapidly expanding CAR-T marketplace, claim this global strategic report to learn the identities and strategies of leading market competitors, access market size data accompanied by market segmentation and forecasts, review clinical trial activity within the sector, assess CAR-T market approvals by region, and importantly, evaluate industry deal-making, emerging technologies, and future directions for the industry at large.

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog
Follow us on LinkedIn – https://www.linkedin.com/company/aarkstore-enterprise/

Global Distributed Antenna Systems (DAS) Market (2018-2023)

Aarkstore Enterprise culminates the newest Market Research Report “Global Distributed Antenna Systems (DAS) Market (2018-2023)

Antenna Systems

Distributed antenna systems (DAS) addresses poor network-coverage related issues in isolated spots, such as inside large buildings. It involves the installation of a network of small antenna throughout the structure, which is connected to a server. The antennae are connected to a controller, which in turn is connected to the base station via the wireless carrier’s network. DAS helps telecommunication companies deal with poor or no coverage, both inside and outside buildings. The global distributed antenna systems market is expected to expand at a CAGR of 12.16%, leading to global revenue of USD 12.2 Bn by 2023.

Businesses are witnessing growing demand for the allocation of a wide variety of wireless technologies in indoor spaces. Telecommunication companies are competing to provide improved connections and services to their customers. They are competing for access rights to indoor venues like stadiums, casinos, and corporate offices. DAS improves wireless connectivity and cell phone reception inside such buildings, thus increasing their resale value. The global distributed antenna systems market segment is based on offering, ownership, verticals, and geography.

‘Offering’ segment insights:
The ‘offering’ segment is further categorized based on components and services. The services segment dominated the market with a share of around 65% in 2017, owing to the benefits of pre-installation. The market for components is projected to expand at a CAGR of 9.1% over 2018–2023.

Ownership segment insights:
The ‘ownership’ segment includes carriers, neutral-hosts, and enterprises. Globally, the carrier ownership model held the largest share (around 44%) of the market in 2017. The neutral-host model is gaining popularity with regard to multi-tenant and third parties’ involvement in deployment and maintenance. The market for neutral-hosts is projected to expand at a CAGR of 10.3% during 2018-2023.

Verticals segment insights:
The verticals segment includes ‘commercial’, ‘public’, and ‘others.’ The public sub-segment held the largest market share (around 45%) within the vertical segment. Growing passenger traffic in railways, airports, and other public places is expected to boost mobile data traffic, which will enhance the requirement for communication networks in such areas. This will drive the demand for distributed antenna systems in the public sector. The commercial vertical is expected to expand due to the increasing adoption of DAS by various corporate offices, to improve connectivity and productivity.

Regional insights:
The global distributed antenna systems market has been divided into the following regions: North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa (MEA).
North America dominated the distributed antenna systems market in 2017, with a share of 32.76%. North America has high Internet penetration, and existing organizations are trying to provide better network coverage across buildings through the installation of DAS. The U.S. is the biggest contributor to this market due to the growing number of smartphone users and the proliferation of technologies like IOT. Both active and passive DAS are being deployed across the country to enhance network connectivity and improve productivity in the workplace. Asia-Pacific is a promising region and is expected to expand at the highest CAGR (14.2%) during 2018–2023.

Companies covered:
o Verizon
o AT&T
o Commscope
o Cobham telecom system
o SOLid Technologies
o American tower corporation
o Sprint
o Boingo Wireless
o Corning
o Zinwave

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog
Follow us on LinkedIn – https://www.linkedin.com/company/aarkstore-enterprise/

Taiwanese Semiconductor Manufacturing Industry, 4Q 2018

Semiconductor

Aarkstore Enterprise culminates the newest Market Research Report “Taiwanese Semiconductor Manufacturing Industry, 4Q 2018

The report finds that the Taiwanese semiconductor manufacturing industry – comprising mainly of the foundry, DRAM, flash memory, and IDM sectors – continued to grow year-on-year and sequentially in the third quarter of 2018.

Despite the limited space for a price rise in memory ICs, the continued demand for NAND flash, coupled with emerging IC demand from automotive electronics, have bolstered the global semiconductor industry which is estimated to have grown over 10% in 2018 compared to 2017. The industrys shipment value is forecast to have reached USD 12 billion in the fourth quarter of 2018, the highest of the year.

CONTENTS

  • Taiwanese Semiconductor Manufacturing Industry Shipment Value, 1Q 2016 – 1Q 2019
  • Taiwanese Semiconductor Manufacturing Industry Shipment Value by Business Type, 1Q 2016 – 1Q 2019
  • Taiwanese Semiconductor Manufacturing Industry 8″”-equivalent Wafer Shipment Volume and Utilization Rate, 1Q 2016 – 1Q 2019
  • Taiwanese Semiconductor Manufacturing Industry Wafer Shipment Volume by Wafer Dimension, 1Q 2016 – 1Q 2019
  • Taiwanese Semiconductor Manufacturing Industry 12-inch Wafer Shipment Volume and Utilization Rate, 1Q 2015 – 3Q 2018
  • Taiwanese Semiconductor Manufacturing Industry 12-inch Wafer Shipment Volume by Business Type, 1Q 2015 – 3Q 2018
  • Taiwanese Semiconductor Manufacturing Industry 8-inch and below Wafer Shipment Volume and Utilization Rate, 1Q 2015 – 3Q 2018
  • Taiwanese Semiconductor Manufacturing Industry 8-inch and below Wafer Shipment Volume by Business Type, 1Q 2015 – 3Q 2018
  • Taiwanese Foundry Industry’s Shipment Value Ranking, 1Q 2016 – 3Q 2018
  • Taiwanese Foundry Industry Shipment Value by Process Technology, 1Q 2016 – 3Q 2018
  • Taiwanese Foundry Industry Shipment Value Share by Process Technology, 1Q 2016 -3Q 2018
  • Taiwanese DRAM Industrys Shipment Value Ranking, 1Q 2016 – 3Q 2018
  • Taiwanese DRAM Industrys 8″”-equivalent Wafer Shipment Volume by Process, 1Q 2016 – 3Q 2018
  • Taiwanese DRAM Industrys 8″”-equivalent Wafer Shipment Volume Share by Process, 1Q 2016 – 3Q 2018
  • Exchange Rate, 1Q 2016 – 3Q 2018
  • Research Scope & Definitions

List Of Tables

This research report presents shipment value forecast and recent quarter review of the Taiwanese semiconductor manufacturing industry.

Companies surveyed in this research are those owning facilities to make MOS (Metal Oxide Semiconductor) wafers in Taiwan, including foundries, DRAM (Dynamic Random Access Memory) makers, flash memory makers, and IDMs (Integrated Device Manufacturers).

The content of this report is based on primary data obtained from interviews, and publicly available information.

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog
Follow us on LinkedIn – https://www.linkedin.com/company/aarkstore-enterprise/

Emerging Gene Therapies – Trends within the Technological, Clinical, Regulatory and Competitive Landscape

Gene Therapies

Aarkstore Enterprise culminates the newest Market Research Report “Emerging Gene Therapies – Trends within the Technological, Clinical, Regulatory and Competitive Landscape

Summary

Latest Report Emerging Gene Therapies – Trends within the Technological, Clinical, Regulatory and Competitive Landscape provides a comprehensive overview of the emerging gene therapy market. The report discusses gene therapy and the technology behind gene editing, outlining the advantages, limitations and current evidence for the platforms under development. The report discusses relevant clinical studies targeting specific therapeutic indications and highlights examples of current challenges within the field, with a focus on therapies that target the eye, liver, and blood.

Additionally, the report provides a background to the CRISPR patent litigation, a key factor within the gene editing company landscape. It provides profiles of six companies developing gene editing platforms, considers the gene therapy interests of the main pharmaceutical companies, and discusses current regulatory trends in the development of gene therapies.

The report explores how emerging gene editing products will compete with established products, their relative competitive strengths, and upcoming value inflection points within the field.

Scope

– What are the key emerging products within the gene therapy landscape?
– Which companies have the strongest pipeline of innovative products?
– How will gene editing disrupt existing gene therapy products?
– What are the regulatory trends for emerging gene therapies?
– What are the interests of pharmaceutical companies within the field?

Reasons to buy

– Achieve an up-to-date understanding of the area, with a comprehensive reference of key products within the gene therapy landscape, compared across technology-specific relevant characteristics such as editing mechanism and delivery vector.
– Conduct competitive analysis using indication-specific, side-by-side comparisons of the latest data for key gene therapy products in the strategically relevant areas of eye, blood, and liver.
– Conduct strategic analysis using an overview of gene therapy specific considerations for evaluating and developing gene therapy products – the CRISPR patent space, emerging regulatory trends, innovation leaders and the interests of pharma in gene therapy.

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog
Follow us on LinkedIn – https://www.linkedin.com/company/aarkstore-enterprise/

%d bloggers like this: